Project Grant R21OD037868
Award Date
7/15/25
Completion Date
4/30/27
Dollars Obligated
$246K
Funding Federal Agency
Office of the Director
Awarding Federal Agency
Aggregate Financial Assistance Data
Federal Grant Program
93.351
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,193,262 to The Regents of the University of California, San Francisco to develop an adeno-associated virus-mediated SGPL1 gene therapy as a potential first-in-class treatment for idiopathic pulmonary fibrosis (IPF). The research aims to confirm the efficacy of this gene therapy in reducing lung fibrosis and downstream profibrotic signaling in mouse models and...
This Project Grant award from the National Center for Advancing Translational Sciences (NCATS) under CFDA 93.350 will provide $463,150 to The Regents of the University of California, San Francisco (UCSF) to establish proof-of-concept for enzyme replacement therapy (ERT) as a lifesaving treatment for sphingosine phosphate lyase insufficiency syndrome (SPLIS), an ultra-rare and often lethal metabolic disorder. The project aims to demonstrate the efficacy of ERT in preserving kidney function and...
The federal Project Grant award R01HD113778, totaling $2,245,254.00, was provided by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865). The award aims to characterize the natural history and progression of Sphingosine Phosphate Lyase Insufficiency Syndrome (SPLIS), an ultra-rare and often lethal metabolic disorder. Key objectives include: 1) Defining the spectrum of...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA Program 93.837 - Cardiovascular Diseases Research provides $695,421 to The Regents of the University of California, San Francisco (UCSF) to conduct research focused on reversing pathogenic remodeling in idiopathic pulmonary fibrosis (IPF). The key objectives are to define pro-reparative differentiation pathways in the fibroblast and stem cell compartments that can be leveraged as therapy, and...
This $110,959 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to understand the mechanisms driving the transition of lipofibroblasts to myofibroblasts in systemic sclerosis, a rare autoimmune fibrosing disease with high mortality. The research aims to define the role of the genes PER3 and CD36 in regulating the lipofibroblast to myofibroblast transition, which is a key driver...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is providing $1,147,992 to The Regents of the University of California, San Francisco (UCSF) to conduct research aimed at advancing precision medicine for acute respiratory distress syndrome (ARDS) and sepsis. The key focus is on deeply phenotyping human samples to understand the functional immune response and pathogen drivers of...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $770,502 to The Regents of the University of California, San Francisco (UCSF) from May 1, 2025 to April 30, 2030. The project aims to understand the molecular mechanisms by which collagen IV regulates TGF-beta signaling in a mouse model of cerebral small vessel disease (CSVD), a...
This Project Grant award of $389,754 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to assess the therapeutic potential of a peptide derived from collagen XVIII for treating lung fibrosis associated with systemic sclerosis (scleroderma). The project aims to evaluate the anti-fibrotic effects of this peptide in a murine model of lung fibrosis, as well as identify the minimal effective dose, optimal...
This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $100,000.00 to the University of Pittsburgh to study the role of cytokines and inflammatory pathways in systemic sclerosis-associated interstitial lung disease (SSc-ILD). The research aims to refine explant culture methodologies and examine the effects of key cytokines, such as TGF-β, PDGF, IL-6, and IL-13, on lung cell gene expression in healthy control and...
This federal Project Grant award of $616,588 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will support research by The Regents of the University of California, San Francisco (UCSF) to exploit a high-precision phenotypic map to illuminate environmental sensing mechanisms of the fungal pathogen Cryptococcus neoformans, which causes fungal meningitis. The research aims to 1) dissect the function of new components of key...